indication
as of 2026-07-01Schizophrenics
Competitive landscape
Competitive set
1
1 approved · 0 pipeline
Projection timeline
actual past → guided future · protection walls overlaid
6 events
2018
2020
2022
2024
2026
2028
2030
2032
2034
2036
2038
2040
2042
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff
Competitive set
resolved drugs with trials in this indicationdrugCompleted
US-approved 2006 · Erzofri extended-release
Phase 21 trial
OwnerJohnson & Johnson
Protection2041
Market size
prevalence as a range, not a number